Lyell Immunopharma has initiated a head‑to‑head CAR‑T clinical trial that will test its experimental cell therapy directly against marketed CAR‑T products. The design aims to generate comparative efficacy and safety data in a space historically dominated by single‑arm pivotal studies. Lyell’s move reflects growing appetite among developers to run more rigorous, comparative trials to demonstrate differential benefit. The company expects the study will clarify positioning for next‑generation cell therapies and inform payer and regulatory discussions on relative value in the CAR‑T market.